|
Dr. Alexandre P. LeBeaut joined Axcan Pharma in May 2006 as senior vice president and chief scientific officer with responsibility for all of Axcan�s drug development activities including the design and execution of Axcan�s clinical development programs and regulatory affairs. He also provides strategic and tactical input for in-licensing opportunities.
Dr. LeBeaut�s broad industry experience with specialty pharmaceutical companies spans more than 18 years. Prior to joining Axcan Dr. LeBeaut held senior scientific positions with Novartis Pharmaceuticals Corporation where he was vice president cardiovascular and metabolism global clinical development and medical affairs. Before occupying this position he served as vice president U.S. clinical development and medical affairs arthritis bone metabolism gastroenterology and women�s health. While at Novartis Dr. LeBeaut served as a project leader on major research programs including the development of Zelnorm� (tegaserod maleate) a drug that was approved in North America for the treatment of women with constipation as a symptom of irritable bowel syndrome.
Before joining Novartis in 2002 Dr. LeBeaut held a number of senior positions with pharmaceutical companies in the U.S. France and Italy including the Schering Plough Research Institute based in Kenilworth New Jersey U.S. where he was a project leader for development programs focusing on cardiovascular and metabolism gastroenterology clinical immunology and infectious diseases.
Dr. LeBeaut is a member of the American Gastroenterological Association the American College of Gastroenterology the American Society of Microbiology the American Society of Critical Care Medicine the American Academy of Pharmaceutical Physicians and the Association of Clinical Research Professionals. He received his medical degree with honors from the University of Paris VII France in 1984 and is a pediatrician by training. | 